B+
Bull case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
ANL
Adlai Nortye GroupFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bullish case is that the market is valuing ANL mainly as a damaged post-BURAN shell even though the company has now funded itself with a $140.0 million PIPE [#PR-2026-02-03], started AN9025 Phase 1 [#PR-2026-02-12], and still guides AN4035 toward mid-2026 IND [#6K-2025-12-29]. If AN9025 shows credible early clinical signals, the current market cap could look too low for a funded multi-asset oncology platform.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -5.1.
What can break
AN4035 IND timing could slip beyond mid-2026, weakening the backup pipeline narrative.
Momentum
93
Value
46
Sentiment
28
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.00 · Bull $16.00 · Bear $6.50Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $29.20
Why
Momentum93 · Δ7d -2.3
Value46 · Δ7d 0.0
Sentiment28 · Δ7d -5.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -5.1.
Contradictions & invalidation
- • AN4035 IND timing could slip beyond mid-2026, weakening the backup pipeline narrative.
- • AN9025 may fail to generate acceptable safety, PK, or early efficacy in Phase 1.
- • The bearish case is that the only late-stage asset already failed and was discontinued [#PR-2025-05-30], so the story has reset to early-stage, high-burn oncology programs with limited human efficacy evidence.
Catalyst clock
2026-05-31
Post-BURAN balance-sheet reset is largely in place
Lead driver: Sentiment · See AI snapshot
Momentum
93
9% active weight
Current posture
7d trendSoftening
Δ7d
-2.3
Δ21d
-4.9
Value
46
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.0
Sentiment
28
62% active weight
Current posture
7d trendSoftening
Δ7d
-5.1
Δ21d
-11.6
Why this grade
Composite grade F. Momentum 92.7 / Value 46.5 / Sentiment 27.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$859.07M
Beta
-
Shares Out
58.73M
P/E (TTM) · Derived
-13.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-12.10
Rev YoY
-
EPS YoY
+45.7%
Gross Margin
-
Op Margin
-133.9%
Net Debt
$2.59M
Current Ratio
9.55
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data